 |
MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (U.S. FDA).
Cipla's...
Every generation of business leaders faces its defining challenge. For some, it was rebuilding after war. For others, it w...
Why every startup should own its website, domain name and customer relationships Starting a business has never been easier...
More Australian employees are prioritising flexible working arrangements over pay and job security, new research from globa...
The corporate landscape in Australia has undergone a permanent structural shift over the past few ...
On Saturday 6 June, parkrun events across the state will be a sea of maroon, with communities str...
Parents rely on baby wipes every day. Whether changing nappies, cleaning little hands or wiping me...
For Australian travellers looking for a destination that combines tropical beaches, ancient histor...
What started out as a fundraiser to help veterans is now having a positive impact on ordinary Aust...
In a world of high-intensity workouts, fitness technology and ever-changing exercise trends, two a...
For many Australian property investors, the initial appeal of self-managing a rental property is bas...